Novartis Q4 Results
↓
↑
Content
Click below to navigate
through the document
pelacarsen - Antisense oligonucleotide (ASO)
targeting Lp(a)
Company overview
Financial review
Conclusions
Appendix
Innovation: Pipeline overview
Financial performance
Innovation: Clinical trials
> Cardiovascular, Renal
and Metabolic
Immunology
Neuroscience
Oncology
Other
Global Health
Abbreviations
References
NCT04023552 Lp(a)HORIZON (CTQJ230A12301)
Indication
Secondary prevention of cardiovascular events in patients with elevated levels of
lipoprotein(a)
Phase
Phase 3
Patients
8323
Primary
Outcome
Measures
Arms
Intervention
Target Patients
Time to the first occurrence of MACE (cardiovascular death, non-fatal MI,
non-fatal stroke and urgent coronary re-vascularization)
TQJ230 80 mg injected monthly subcutaneously or matched placebo
Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically
significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL
Readout
Milestone(s)
2025
Publication
TBD
□ NOVARTIS Reimagining Medicine
Novartis Q4 Results | January 31, 2024
53View entire presentation